Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.In an expanded collaboration agreement, BioTrove has agreed to use its proprietary RapidFire lead discovery service on an undisclosed number of targets identified by Schering-Plough.
Subscribe to our email newsletter
RapidFire lead discovery is a mass spectrometry-based technology that enables the high throughput screening of biochemical assays. The use of mass spectrometry allows for label-free screening of challenging and intractable drug targets using native substrates.
The system can analyze assays by mass spectrometry at throughputs of four to eight seconds per sample, providing a dramatic increase in throughput over conventional liquid chromatography-mass spectrometry systems.
“With RapidFire our collaborators have been able to pursue many drug targets that were previously inaccessible due to technical or economical difficulties,” said Dr Can “Jon” Ozbal, director of the RapidFire program at BioTrove.
Financial terms and the length of the relationship have not been disclosed.